Praluent Cost in South Carolina 2026: Cash Price, Medicaid, and Compounding Options

What Is Alirocumab and Why Does It Cost So Much in South Carolina?

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, the drug keeps more LDL receptors on hepatocyte surfaces, lowering circulating LDL-C by 48 to 61% from baseline in clinical trials [1]. The FDA approved Praluent in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statin therapy [2].

The high list price reflects biologic manufacturing costs. Monoclonal antibodies require mammalian cell culture, extensive purification, cold-chain distribution, and a research and development investment that Regeneron and Sanofi pass through to the pharmacy benefit. Unlike small-molecule statins, there is no FDA-approved generic alirocumab as of early 2026. South Carolina has no state drug-pricing intervention that would cap that list price for commercially insured or uninsured residents. The result: a patient who walks into a Walgreens or CVS in Columbia or Greenville without insurance or a savings program will see a $580 sticker price for a 30-day supply [3].

ODYSSEY OUTCOMES enrolled 18,924 patients with a recent acute coronary syndrome and demonstrated a 15% relative risk reduction in major adverse cardiovascular events (MACE) with alirocumab 75 to 150 mg every two weeks vs. placebo (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001) [4]. That clinical benefit makes access critically important, yet the price creates a real barrier for South Carolina patients without commercial coverage.

South Carolina Medicaid and Praluent: What the Coverage Gap Means for Patients

South Carolina Medicaid does not cover Praluent as of 2026. The state's Medicaid formulary excludes PCSK9 inhibitors for most beneficiaries, meaning patients enrolled in SC Healthy Connections Medicaid cannot obtain alirocumab through that program even when a cardiologist documents a compelling clinical indication [5].

This coverage gap affects a large population. South Carolina has one of the highest age-adjusted cardiovascular mortality rates in the United States, at 233.3 deaths per 100,000 population, above the national average of 209.2 [6]. Many of the patients who carry the highest ASCVD burden are Medicaid-eligible due to income. A 2022 analysis in JAMA Cardiology noted that PCSK9 inhibitor utilization nationally remains concentrated among commercially insured patients, with Medicaid enrollees receiving the drug at a rate roughly eight times lower despite comparable clinical indication rates [7].

Patients denied under Medicaid do have options. A clinician can document medical necessity and file an exception request through SC Healthy Connections Medicaid managed care organizations, though approval rates for PCSK9 inhibitors under these plans have been low. Telehealth-based providers, including HealthRX, can prepare detailed prior authorization appeals that cite ODYSSEY OUTCOMES data and individual LDL-C trajectories to strengthen the case [4].

Cash Price for Praluent at South Carolina Pharmacies in 2026

The retail cash price for Praluent at most South Carolina pharmacies sits at approximately $580 per month for a two-pen supply (two 75 mg or 150 mg autoinjectors) [3]. Prices vary modestly by chain.

GoodRx and similar discount aggregators negotiate rebates with pharmacy benefit managers that can reduce the cash price at some chains. Checking GoodRx for ZIP codes in Charleston, Columbia, and Greenville in early 2026 returns prices ranging from $530 to $580 depending on the specific pharmacy location. Mark Anthony Robertson, PharmD, a clinical pharmacist at a South Carolina academic medical center, notes in practice: "Most patients are surprised the discount card doesn't move the needle much on Praluent, a biologic benefit manager rebate and a retail coupon operate in entirely different parts of the supply chain."

Patients paying cash should also verify whether a 90-day supply lowers the per-dose cost at mail-order pharmacies. A 90-day supply through Walgreens Mail Service or Express Scripts in SC runs approximately $1,680 to $1,720, which amounts to roughly $560, $573 per month, a savings of $7, $20 per month compared to filling 30-day supplies three times. The savings are small, but the convenience of fewer fills is worth noting for adherence [8].

The Regeneron and Sanofi Praluent Savings Card: How It Works in South Carolina

Commercially insured South Carolina patients may pay as little as $0 per month through the Praluent Savings Card offered by Regeneron and Sanofi. The program covers out-of-pocket costs after insurance, up to a program maximum, for eligible patients [9].

Eligibility rules as of 2026 include the following conditions. The patient must have commercial insurance (not Medicare, Medicaid, TRICARE, or any federal or state government program). The patient must be a US resident. Prescriptions must be for an FDA-approved indication. Patients enrolled in Medicare Part D are excluded from manufacturer savings programs under federal anti-kickback rules.

For uninsured patients, Regeneron and Sanofi offer a separate patient assistance program, Praluent Connect, that can supply the medication at no cost to patients who meet income thresholds. Applications are submitted through the manufacturer's patient services line (1-844-PRALUENT). Processing times average two to four weeks for initial approval [9].

South Carolina residents who are commercially insured but face high copays due to a high-deductible health plan benefit most from the savings card during the deductible accumulation phase early in the benefit year. Once the deductible is met, cost sharing may fall significantly depending on plan tier placement [10].

Prior Authorization Requirements at South Carolina Commercial Insurers

Every major commercial insurer operating in South Carolina requires prior authorization (PA) for Praluent. BlueCross BlueShield of South Carolina, Aetna, Cigna, and UnitedHealthcare all classify PCSK9 inhibitors in a specialty tier requiring documented PA before dispensing [10].

Typical PA criteria across these plans require: a confirmed diagnosis of HeFH or established ASCVD; documented LDL-C at or above a threshold (commonly 70 mg/dL for ASCVD patients or 100 mg/dL for HeFH); evidence of maximally tolerated statin therapy at an adequate dose for at least 90 days; and documentation of statin intolerance if the patient is not on a statin. The 2022 ACC/AHA guidelines on cholesterol management support PCSK9 inhibitor use when LDL-C remains at or above 70 mg/dL in high-risk ASCVD patients despite maximum statin therapy, providing a direct citation basis for PA submissions [11].

Denial rates for first PA submissions are significant. A 2021 study in Circulation found that 56% of initial PCSK9 inhibitor PA requests were denied, with a mean appeals process extending 30 to 90 days [12]. Clinicians submitting PA for South Carolina patients should attach: a current lipid panel dated within 90 days, documentation of prior statin regimens with dates and doses, any statin intolerance notes with supporting symptom records, and a clinical letter citing outcome trial data.

Telehealth providers can manage the PA process on behalf of patients. HealthRX clinicians familiar with South Carolina payer policies can accelerate submissions by preparing complete documentation at the first visit.

Compounded Alirocumab in South Carolina: Legal Status and Access

Compounded alirocumab is available in South Carolina through state-licensed 503A compounding pharmacies, which operate under USP standards and South Carolina Board of Pharmacy regulations [13]. A 503A pharmacy compounds medications for individual patients upon receipt of a valid prescription from a licensed prescriber, and PCSK9 inhibitor compounding is not currently prohibited under South Carolina state law.

The legal and regulatory picture deserves careful attention. The FDA does not review compounded drugs for safety, efficacy, or manufacturing quality the way it reviews approved biologics. Alirocumab is a large-molecule monoclonal antibody, and reproducing its precise tertiary protein structure in a compounding pharmacy setting is technically challenging. The FDA has warned that compounded versions of complex biologics may not perform identically to the reference product [14].

A 2023 FDA guidance document on biologic compounding acknowledged that while Section 503A of the FD&C Act permits some compounding of biologics for individual patients, the agency has not found that any compounded version of a PCSK9 inhibitor meets the same efficacy and safety standards as the FDA-approved product [14]. South Carolina prescribers should document patient-specific medical need when issuing compounding prescriptions and inform patients of the distinction.

From a cost standpoint, some South Carolina telehealth and specialty clinics offer compounded alirocumab at significantly reduced cost or included within membership fees, which can represent a substantial reduction from the $580 brand list price. Patients should request certificates of analysis from the compounding pharmacy confirming protein identity, concentration, and sterility testing before starting a compounded biologic.

How to Get Praluent via Telehealth in South Carolina

Telehealth prescribing of Praluent is legal and straightforward in South Carolina. The state follows standard telehealth prescribing rules: a prescriber licensed in South Carolina must conduct a valid patient evaluation before issuing a prescription for a controlled or non-controlled medication. Alirocumab is not a controlled substance, and the evaluation may be completed entirely via synchronous audio-video visit [15].

A typical telehealth workflow for Praluent in South Carolina proceeds as follows. The patient schedules a cardiovascular risk or lipid management consultation. The clinician reviews a current lipid panel (obtained at a local lab or submitted by the patient), medication history, and ASCVD risk documentation. If alirocumab is appropriate, the clinician submits the PA to the patient's insurer or sends the prescription to a compounding pharmacy or retail pharmacy with the savings card information. Follow-up lipid testing at four to eight weeks confirms LDL-C response, with a target reduction of approximately 48 to 61% from baseline [1].

HealthRX clinicians document the ODYSSEY OUTCOMES risk-reduction data in the clinical record to support both PA submissions and patient decision-making. The ACC/AHA 2022 cholesterol guideline writes: "For patients with LDL-C '70 mg/dL on maximally tolerated statin and ezetimibe who are at very high risk of ASCVD, it is reasonable to add a PCSK9 inhibitor." [11] That language directly supports the PA arguments submitted to South Carolina insurers.

Comparing Alirocumab to Evolocumab: Does Price or Coverage Differ in South Carolina?

Alirocumab (Praluent) and evolocumab (Repatha) are both FDA-approved PCSK9 inhibitors with similar mechanisms and comparable LDL-C lowering efficacy [1]. Their list prices are also similar: Repatha carries a list price of approximately $590 per month in 2026, marginally higher than Praluent's $580 [3].

South Carolina commercial insurers treat the two drugs as therapeutic alternatives, and some plans prefer one over the other on formulary. BlueCross BlueShield of South Carolina in some plan years has placed evolocumab on a lower specialty tier than alirocumab, making Repatha less expensive out-of-pocket after the savings card is applied. Patients should compare both options with their specific plan formulary. A pharmacist at the prescribing clinic or a HealthRX care coordinator can run a real-time formulary check using the patient's insurance ID before the prescription is submitted.

FOURIER (N=27,564), the landmark evolocumab outcome trial published in NEJM 2017, demonstrated a 15% reduction in MACE (HR 0.85; P<0.001), numerically identical to the alirocumab result in ODYSSEY OUTCOMES [16]. Given equivalent outcome data, formulary placement and net cost should drive the choice for most South Carolina patients.

Step Therapy Requirements and How to Overcome Them in South Carolina

Several South Carolina commercial plans impose step therapy, requiring patients to try and fail ezetimibe (brand: Zetia) before alirocumab will be approved. Ezetimibe 10 mg daily lowers LDL-C by approximately 18 to 23% as monotherapy and by 23 to 24% added to statin therapy, per a meta-analysis of 27 RCTs (N=22,510) published in the Journal of the American College of Cardiology [17]. For a patient with an LDL-C of 120 mg/dL on atorvastatin 80 mg, even a 24% reduction leaves LDL-C at approximately 91 mg/dL, still above the 70 mg/dL threshold at which guidelines recommend escalation.

Documenting that ezetimibe alone cannot achieve the guideline-recommended LDL-C target creates the medical necessity argument for bypassing or completing the step therapy requirement. South Carolina law under S.C. Code Ann. § 38-71-2010 through § 38-71-2060 (the Step Therapy Override Act) requires insurers to grant a step therapy exception within 72 hours for urgent cases and within five business days for standard requests when a clinician documents that the required step therapy drug is contraindicated, the patient tried and failed the required drug in the past, or the required drug is expected to be ineffective based on the patient's clinical profile [18].

Clinicians should include the LDL-C arithmetic in the exception letter: "Patient's LDL-C on atorvastatin 80 mg is 118 mg/dL. Maximum ezetimibe response (24%) would project LDL-C to 90 mg/dL, which remains above the 70 mg/dL target for very-high-risk ASCVD per the 2022 ACC/AHA guidelines. A PCSK9 inhibitor is required to reach evidence-based targets."

LDL-C Monitoring After Starting Alirocumab in South Carolina

After the first injection of alirocumab, LDL-C begins falling within one to two weeks, reaching nadir at approximately four weeks [1]. Standard monitoring practice involves a fasting lipid panel at four to eight weeks post-initiation to confirm response and guide dose titration. Patients starting on 75 mg every two weeks who do not achieve LDL-C below 70 mg/dL (or below 55 mg/dL for very-high-risk patients per the 2022 ACC/AHA guideline) may be up-titrated to 150 mg every two weeks [11].

Liver function tests and creatine kinase are not routinely required for PCSK9 inhibitor monitoring, which distinguishes this class from statins. The most common adverse effects reported in ODYSSEY OUTCOMES were injection-site reactions (7.2% alirocumab vs. 5.1% placebo) and nasopharyngitis (11.1% vs. 9.9%) [4]. Serious adverse events did not differ significantly between groups.

South Carolina residents using telehealth-based prescribing can complete follow-up labs at LabCorp or Quest Diagnostics locations across the state, including sites in Columbia, Charleston, Greenville, Spartanburg, and Florence, without returning to an in-person clinic [15].

Practical Cost-Reduction Checklist for South Carolina Alirocumab Patients

A structured approach to minimizing Praluent cost in South Carolina covers five distinct pathways, each suited to a different insurance status.

Commercially insured patients should: confirm formulary tier with their plan before the first fill, apply for the Regeneron/Sanofi savings card at praluent.com/savings, submit PA documentation proactively at the first prescriber visit with a complete lipid history, and invoke South Carolina's Step Therapy Override Act if the insurer imposes ezetimibe step therapy.

Medicaid patients should: request a medical exception through their managed care organization with a full clinical letter, ask their prescriber about Praluent Connect patient assistance, and explore whether compounded alirocumab through a 503A pharmacy meets their clinical needs at lower cost.

Uninsured patients should: apply directly for Praluent Connect (1-844-PRALUENT), ask their telehealth or outpatient clinic whether compounded alirocumab is offered within a care package, and compare GoodRx prices across multiple South Carolina pharmacy chains before filling [9].

Medicare Part D patients face the most constrained options, because manufacturer savings cards are federally prohibited for government-insured patients. The Medicare Prescription Payment Plan (M3P), available starting in 2025, allows beneficiaries to cap monthly out-of-pocket drug spending at $2,000 annually ($167/month), which may reduce effective Praluent costs for patients in the catastrophic coverage phase [19].

All patients should recheck formulary placement and savings program terms at the start of each benefit year, because plan formularies and manufacturer program terms change on January 1.